ライフサイエンスコーパス: renal function

1 related myocardial infarction, and worsening renal function).

2 nction of HPS proteins could directly impact renal function.

3 ted daily as the primary method of measuring renal function.

4 dabigatran in >98% of patients regardless of renal function.

5 with replete vitamin B-12 status and normal renal function.

6 higher in patients with initially preserved renal function.

7 etion (NAE) capacity indicates a decrease in renal function.

8 y compared with control patients with normal renal function.

9 less and adequate haematologic, hepatic, and renal function.

10 vascular disease, most of whom had preserved renal function.

11 linosis, which contributes to the decline in renal function.

12 ears; and adequate bone marrow, hepatic, and renal function.

13 istory of liver disease and deterioration of renal function.

14 in part be responsible for the impairment of renal function.

15 nhanced inflammation, fibrosis, and impaired renal function.

16 scular disease, heart failure, and degree of renal function.

17 iovascular disease and mostly with preserved renal function.

18 h exert cardiodepressive effects and improve renal function.

19 yte effacement is delayed, prolonging normal renal function.

20 iduals with diabetic kidney disease and poor renal function.

21 wever, concentrations increase with impaired renal function.

22 nts, regardless of having impaired or normal renal function.

23 ng patients with early disease and preserved renal function.

24 culminating in progressive deterioration of renal function.

25 n RRMM patients regardless of their baseline renal function.

26 the strongest risk factor for future loss of renal function.

27 h models, Stiripentol improved significantly renal function.

28 sing MCP-1 and KIM-1 levels precedes loss of renal function.

29 ction, patient and graft survival rates, and renal function.

30 oxyglucose uptake, as well as female sex and renal function.

31 in in comparison with placebo, regardless of renal function.

32 es: body mass index, sex, age, diabetes, and renal function.

33 dialysis frequency, blood flow, and residual renal function.

34 onredundant contribution of Epac isoforms to renal function.

35 e universally attempted after LT to preserve renal function.

36 with a ventilated control group with normal renal function.

37 H(2)S treatment reduced SBP and improved renal function.

38 of age, sex, body mass index, and liver and renal function.

39 e kidney injury than in patients with normal renal function.

40 eeks; and adequate bone marrow, hepatic, and renal function.

41 MMA showed notable, increases with impaired renal function.

42 essure was consistent regardless of baseline renal function.

43 ins immunosuppressive efficacy and preserves renal function.

44 for the 5-mg dose in patients with preserved renal function.

45 h) for 7-14 days; regimens were adjusted for renal function.

46 iated with serum levels of IS independent of renal function.

47 onin (hs-cTn) concentrations irrespective of renal function.

48 w risk, and better correlated with follow-up renal function.

49 emia, though none had rapid deterioration of renal function.

50 several microRNAs correlated with indexes of renal function.

51 ned whether this association was modified by renal function.

52 ameters were normal, as were his hepatic and renal function.

53 tantially with increasing age and decreasing renal function.

54 f renal cells is an important determinant of renal function.

55 fer a benefit in those with severely reduced renal function.

56 ed in fasting glucose, insulin, ketones, and renal function.

57 sted a role for additional genes involved in renal function.

58 and safe anticoagulants in KTRs with stable renal function.

59 time did not affect the risk of PNF or poor renal function.

60 audition, regulation of blood pressure, and renal function.

61 expression, and improved tubular repair and renal function.

62 ipidemia, the metabolic syndrome or impaired renal function.

63 ed increased tubular injury and deteriorated renal function.

64 ase 2019 (COVID-19) display abnormalities in renal function.

65 t not in renal hypoxia, TNF-alpha levels, or renal function.

66 d with diverse etiologies and abrupt loss of renal function.

67 d glomerular filtration rate, overestimating renal function.

68 to sodium and water retention and worsening renal function.

69 epithelium that leads to the sudden loss of renal function.

70 in the presence of impaired respiratory and renal functions.

71 encode various proteins with renal and extra-renal functions.

72 ch other that controlling blood pressure and renal functions.

73 are were hypokalemia (23% vs 25%), worsening renal function (21% vs 20%), headache (26% vs 10%), dizz

74 Less than 50% of patients with normal renal function achieve this exposure, and it is associat

75 nvestigation as a more meaningful measure of renal function after critical illness.

76 SLN) mice with Tris DBA resulted in improved renal function, albuminuria, and pathology, including me

77 ex (aircraft, road traffic Lden, and PM2.5), renal function and "allostatic load" (all exposures).

78 y common genetic associations that influence renal function and all-cause CKD, but these explain only

79 All animals underwent analysis of renal function and biomolecular phenotyping at 24 h, 48

80 All animals underwent analysis of renal function and biomolecular phenotyping.

81 (8-OHdG) and F2-isoprostane, and measures of renal function and blood pressure among children with CK

82 n number is a major determinant of long-term renal function and cardiovascular risk.

83 We examined renal function and cell type composition of control litt

84 ith medical co-morbidities, such as impaired renal function and diabetes.

85 conditions thus providing key information of renal function and diagnosis of various kidney and liver

86 Renal function and donor-specific HLA-antibodies remaine

87 Renal function and histologic morphology were evaluated.

88 Renal function and histology, complement activation, and

89 has been proposed as a link between abnormal renal function and impairment of cardiac function and ca

90 ceptor) activators were reported to preserve renal function and improve mortality in AKI patients, al

91 were associated with progressive decline in renal function and incident ESRD in patients with ADPKD,

92 iorated by Opn(-/-) coincident with improved renal function and increased expression of Ogdhl.

93 sis, cardiac wall stress, myocardial injury, renal function and inflammation, are associated with ear

94 s a critical regulator of cardiovascular and renal function and is an important model for studies of

95 ry, fluid bolus therapy transiently improved renal function and medullary PO2, as also reflected by i

96 5 mg twice daily) in patients with preserved renal function and might be a reasonable alternative to

97 mone (GH) plays a significant role in normal renal function and overactive GH signaling has been impl

98 CysC may improve assessment of renal function and prediction of early postoperative out

99 Physicians should closely monitor renal function and serum ferritin, use the lowest effect

100 luate the association between variability of renal function and the risk of developing AF among the g

101 the expression of RTN1A correlates with the renal function and the severity of kidney injury in pati

102 ariables of hepatic, metabolic, cardiac, and renal function, and 90-day mortality were measured.

103 no atrial fibrillation 5.75:1) and with age, renal function, and body mass index but not with left ve

104 to LT, considering their functional status, renal function, and cardiovascular risk.

105 WRF) and renal tubular injury, postdischarge renal function, and clinical outcomes is unknown.

106 d further by including measures of glycemia, renal function, and diabetes mellitus treatment (C stati

107 her baseline blood pressure, better baseline renal function, and fewer comorbidities.

108 ore often had coronary artery disease, worse renal function, and impaired left ventricular ejection f

109 f renal injury, improvement in indicators of renal function, and improved delivery of vascular-target

110 d on transplant age, gender transplant year, renal function, and inotropic support at transplant to f

111 d fluid transport, neuroendocrine control of renal function, and modeling of numerous human renal con

112 nt failure rates, delayed graft function and renal function, and patient and graft survival were not

113 ecting myocardial stress, myocardial injury, renal function, and systemic inflammation.

114 Chronicity (ci + ct + cg + cv) scores, renal function, and the burden of renal disease measured

115 the effect of RDN on mean arterial pressure, renal function, and the reflex response to hemorrhage in

116 ncer Database (NCDB), to determine long-term renal function, and to determine the risk of metachronou

117 es the effects of rifaximin on hemodynamics, renal function, and vasoactive hormones.

118 Body weight, age, hepatic and renal functions, and the UGT2B7 rs62298861 polymorphism

119 rapy maintain significantly better long-term renal function as well as significantly reduced CAV than

120 ess the safety, tolerability, and effects on renal function as well as therapeutic efficacy of prosta

121 nses promoted renal scarring and compromised renal function, as indicated by elevated serum creatinin

122 ron emission tomography, echocardiogram, and renal function ascertainment at Brigham and Women's Hosp

123 In two mouse models of CKD, the decline in renal function associated with the accumulation of IS in

124 l compared with 8.3% of patients with normal renal function at baseline.

125 e patients is often mild and does not impact renal function at day 30, while infection/ sepsis is the

126 t graft loss in patients who showed a stable renal function at the day of biopsy.

127 Renal function at week 52 was similar in both arms.

128 There were no differences in 1-year renal function, Banff chronicity score at 3- and 12-mont

129 There were no differences in 1-year renal function, Banff chronicity score at 3- and 12-mont

130 A prospective study of renal function before and after aortic stent-graft treat

131 HMP did not result in significantly improved renal function, beneficial effects were found in terms o

132 of acute rejection, nutritional therapy, and renal function between "Control group (with stoma)," n =

133 rrelated with a composite clinical endpoint (renal function, biopsy-proved acute rejection, >=grade 2

134 Secondary outcomes were improvement in renal function, blood pressure (BP), and complications.

135 efficiently achieved and not only preserved renal function but also partially reversed kidney lesion

136 s with procedures were similar regardless of renal function, but patients with severe renal impairmen

137 se (ADPKD) experience progressive decline in renal function, but rates of decline and outcomes vary g

138 tamin B-12-replete subpopulation with normal renal function, but still age-dependent.

139 R mice treated with KMP2-EVs showed improved renal function by reducing tubular cell apoptosis, pro-i

140 tary antioxidants and their association with renal function characterised by estimated glomerular fil

141 ghtened early allograft chronicity and worse renal function compared with those with No-TCMR.

142 serum levels of OPN and TIMP-1, recovery of renal function correlated with decreases in the level of

143 outcomes were compared according to baseline renal function (creatinine clearance: normal >=80, mild

144 on (prior procedures [P], age [A], depressed renal function [D], immunocompromised [I], and procedure

145 Proteinuria is associated with renal function decline and cardiovascular mortality.

146 RAP)-deficient mice displayed age-associated renal function decline and tubulointerstitial fibrosis.

147 the effect of such a program on the rate of renal function decline in patients with CKD (stages 3-5)

148 e it can reduce proteinuria and hence retard renal function decline, but the proteinuria reduction ef

149 asculature and contributing to aging-related renal function decline.

150 a potential therapeutic target to attenuate renal function decline.

151 their relationship to CKD status and further renal function decline.

152 sk of both ischemic stroke and hemorrhage as renal function declines, complicating the decision to in

153 urinary exosomes differentially expressed as renal function declines.

154 Renal autoregulation maintains stable renal function despite BP fluctuations and protects glom

155 e into demonstrable gains in preservation of renal function, despite an apparent trend to improvement

156 Hypertension often occurs before renal function deteriorates in autosomal dominant polycy

157 (CSC, n=446): patients developing new-onset renal function deterioration 7.7 +/- 5.6 years posttrans

158 Renal function did not worsen on LDV/SOF regimens with T

159 ive regimen has been demonstrated to improve renal function early after heart transplantation, but lo

160 r primary nonfunction (PNF; n = 37) and poor renal function (estimated glomerular filtration rate < 3

161 Healthcare provision included annual HbA1c, renal function (estimated glomerular filtration rate [eG

162 There was no difference in renal function (estimated glomerular filtration rate and

163 Finally, we focus on predonation renal function evaluation, a criteria that remain centra

164 ate inflammatory genes for associations with renal function expressed as the estimated glomerular fil

165 In addition to renal functions, extrarenal organs may be affected from

166 udy, the effects of serelaxin on cardiac and renal function, fibrosis, inflammation and lipid accumul

167 gy and point to CD47 as a target to preserve renal function following injury.

168 disease, the ability to predict recovery of renal function following liver transplantation (LT) rema

169 nosis for glycaemic progression and baseline renal function for renal progression).

170 e associated with NS play conserved roles in renal function from flies to humans.

171 Orai1 blockade significantly protected renal function from IR, attenuated high-salt-induced AKI

172 Even in healthy individuals, renal function gradually declines during aging.

173 1) or at least one examination and impaired renal function (group 2).

174 Control groups with normal and impaired renal function (groups 3 and 4) without history of contr

175 utcomes) of DOACs in a cohort of KTRs with a renal function >30 mL/min.

176 Moreover, renal function has never been compared to conventionally

177 m in the kidney; however, its importance for renal function has only recently emerged.

178 lar structure and function (GNB3, CDON), and renal function (HAS2 and HAS2-AS1, SLIT3).

179 Patients with ALD and impaired renal function have a higher risk of graft loss and deat

180 eds affected with atherosclerosis), impaired renal function, heart failure, and/or diabetes mellitus,

181 safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, a

182 Rates of worsening renal function, hyperkalemia, symptomatic hypotension, a

183 The rates of worsening renal function, hyperkalemia, symptomatic hypotension, a

184 hort, smoking status, pack-years of smoking, renal function, hypertension, diabetes, and medications.

185 i) Intestinal and renal histopathology; (ii) Renal function; (iii) Cellular signaling changes; (iv) O

186 docyte dysfunction is a major contributor of renal function impairment in DN.

187 rom patients with renal TILs correlated with renal function impairment.

188 effect of administering oxygen during HMP on renal function in a porcine DCD model.

189 Here we evaluated Kd56 vs Vd by baseline renal function in a post hoc exploratory subgroup analys

190 7 that have not previously been analysed for renal function in an animal model.

191 Fibrosis is a major cause of loss of renal function in autosomal dominant polycystic kidney d

192 mplete reversal of hypertension and improved renal function in CKD-RDN sheep (p < 0.0001 for 2 and 5

193 tissue damage at systemic level and improved renal function in conditioned groups compared to control

194 reversal and outcomes according to baseline renal function in dabigatran-treated nondialysis patient

195 oth T-AN and H-AN negatively correlated with renal function in diabetic patients and they may serve a

196 CysC) has shown superiority in assessment of renal function in disease states characterized by muscle

197 It provides new insight into worsening renal function in HCM, and active surveillance for renal

198 holine, and TMAO levels were associated with renal function in humans and differed significantly acro

199 ized that the hepatokine fetuin-A may impair renal function in non alcoholic fatty liver disease (NAF

200 er CKD incidence rates and slower decline in renal function in nondiabetic CKD for premenopausal wome

201 d routine monitoring of serum potassium, and renal function in patients treated with a mineralocortic

202 0L and sCD40R are associated with changes in renal function in patients with CKD.

203 mine the effect of RDN on blood pressure and renal function in patients with RH in comparison to medi

204 (rs872914/A, rs941757/G, and rs941758/A) and renal function in patients with type 1 diabetes.

205 ndothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high

206 Pool walking may improve renal function in pregnant women partly through the supp

207 med to examine the effect of pool walking on renal function in pregnant women.

208 ential for clinically significant changes in renal function in relation to exposure to common environ

209 After 2 decades, she has normal renal function in the absence of ongoing systemic immuno

210 munity, Troha et al. identify a key role for renal function in the clearance of circulating Lys-type

211 o be taken into consideration when assessing renal function in the ICU.

212 same hospitalisation) significantly worsened renal function in the late follow-up and should be avoid

213 s over time, which have been shown to affect renal function in the long term.

214 be used to monitor KT recipients with stable renal function, including after treatment for subAR, pot

215 Creatinine was measured as renal function index after and before the procedure.

216 who are vitamin B-12-replete and have normal renal function indicate the need for age-specific MMA re

217 to take information on metabolic status and renal function into account as potential confounders.

218 tion of the interactions between thyroid and renal function is a challenge for clinicians involved in

219 Renal functioning is an important determinant of dosing

220 into four subsets of variables-inflammation, renal function, liver function, and blood glucose.

221 Clinical renal function measures included estimated glomerular fi

222 Regardless of renal function, median reversal measured by dilute throm

223 related to anthropometry, cardiovascular and renal function, metabolism, and inflammation were select

224 dings suggest that, irrespective of baseline renal function, MRI with gadobenate dimeglumine is a non

225 ed for risk factors including age, diabetes, renal function, N-terminal pro-b-type natriuretic peptid

226 orsened eGFR (>/=10% lower), or no change in renal function (neither).

227 ter the KTx, the patient is well with normal renal function, no immunosuppression and continues eculi

228 ontribute to the improvements in cardiac and renal function observed with this class of therapeutics.

229 ine uACR, corresponding to an annual loss of renal function of 3% per year.

230 Renal function of native kidneys was within CKD stages 1

231 However, the markers of renal function of the Ep group were detected slightly im

232 Impairment of renal function often occurs in patients with liver disea

233 higher mortality in patients with worsening renal function on follow-up.

234 ation (AF), the impact of the variability of renal function on the risk of incident AF is unknown.

235 by SIR-based early CNI minimization protects renal function only short-term after LT in the intention

236 ariants in proteinuric patients with reduced renal function or focal segmental glomerulosclerosis.

237 t in the context of genetic correlation with renal function or resting and postexercise heart rate de

238 ferences between groups with respect to age, renal function, or biomarkers except for D-dimer (median

239 duce fibrosis by 50% and prevent the loss of renal function over 3 months.

240 llent patient and graft survival, and stable renal function over 4 years.

241 The authors observed no deterioration in renal function over time in patients with moderate or mo

242 mL/min) was associated with greater loss of renal function per year of follow-up (P = 0.007).

243 iation between tacrolimus IPV on (1) loss of renal function per year of follow-up and (2) cytomegalov

244 mption leads to overproduction of urates and renal function plays a critical role in serum uric acid

245 ficant difference between groups in terms of renal function, proteinuria, or biopsy-proven acute reje

246 However, decongestion and renal function recovery at 60 days were superior in pati

247 cations, whereas a delayed one may allow for renal function recovery in some patients without need fo

248 tions (such as catheter infection) and favor renal function recovery.

249 In addition, G2 recipients showed superior renal function, reduced sC5b-9, and reduced urinary neut

250 Improvement and sometimes cure with renal function restoration are now possible.

251 patients cure or improvement occurred after renal function restoration.

252 Results In patients of all ages with normal renal function, routine PN yielded the longest life expe

253 Residual renal function (RRF) confers survival in patients with E

254 CNI withdrawal after HTx on albuminuria and renal function seem dissociated; hence, the clinical sig

255 All parameters of renal function (serum creatinine, blood urea nitrogen, a

256 function in HCM, and active surveillance for renal function should be considered.

257 eatinine has been considered as indicator of renal function specifically after dialysis, thyroid malf

258 ols with type 2 diabetes mellitus and normal renal function (T2DNRF; n = 15).

259 alpha, interleukins, hemogram, and liver and renal function tests were performed at days 0 and 5.

260 clinically evaluated by ultrasonography and renal function tests.

261 ility, menstrual irregularities and abnormal renal function tests.

262 regimen had less effect on bone density and renal function than the other regimens.

263 KO mice into CD4 KO or WT mice led to worse renal function than transfer of WT CD4(+) T cells.

264 lomerulonephritis and stage 1 CKD (preserved renal function) than in healthy volunteers (mean, 1.88 [

265 The magnitude of decline in renal function that should be tolerated during intensive

266 t graft loss in patients who showed a stable renal function the day of biopsy.

267 Among ICU patients with stable renal function, the benefit of using sodium bicarbonate

268 Compared with patients with normal renal function, those with impaired renal function were

269 a-lactam therapy, particularly with impaired renal function, though no studies have reported ceftarol

270 olecular and immunohistochemical analysis of renal function, tissue damage, and key molecular targets

271 tifying patients at risk of early decline in renal function to target and intensify renoprotective tr

272 sly reported integrated model of cardiac and renal functions to account for the fluid exchange betwee

273 ification by glucose-lowering medication and renal function, to receive oral semaglutide (dose escala

274 Health Sciences Center and established their renal function trajectories.

275 singly recognized as important modulators of renal function under physiological and pathophysiologica

276 yperuricaemic with evidence of deteriorating renal function, unless specific contraindications exist.

277 d the efficacy of beta-blockers according to renal function using estimated glomerular filtration rat

278 ivaroxaban (20 mg/d or 15 mg/d, according to renal function) versus dose-adjusted VKAs (target intern

279 Renal function was already impaired at baseline in 43.7%

280 The variability of renal function was defined as GFR-VIM, which is variabil

281 Renal function was further quantified by measuring tubul

282 However, renal function was normal in all cases.

283 ed, and no clinically significant decline in renal function was observed.

284 Renal function was preserved at 3 months after LT in the

285 At last follow-up, renal function was similar between the groups.

286 r of the endothelial extracellular matrix in renal function, we generated mice with an endothelium-sp

287 Data about acute rejection, DSA, and renal function were collected.

288 Risk factors for poor renal function were donor body mass index (OR = 1.2; P <

289 on (APACHE) II score, severity of sepsis and renal function were enrolled.

290 h normal renal function, those with impaired renal function were older, were more often women, and ha

291 Shorter fasting times and impaired renal function were significantly associated with higher

292 low-dose immunosuppression; however, AR and renal function were significantly improved when given hi

293 iciency, neutropenia, or abnormal hepatic or renal function, were randomly allocated (2:1) to receive

294 months of follow-up, the patient has stable renal function with a serum creatinine of 1.6 mg/dL.

295 MIOX-TG mice had worsening renal functions with kidneys having increased oxidant/ER

296 de of benefit of SGLT2i varied with baseline renal function, with greater reductions in hospitalisati

297 Of these, 70.3% experienced improved renal function within 48 hours.

298 with chronic kidney disease (CCKD) and poor renal function without diabetes (n = 18).

299 failure patients with preexisting worsening renal function (WRF) and renal tubular injury, postdisch

300 er liraglutide was associated with worsening renal function (WRF).